Showing 1911-1920 of 5771 results for "".
- Bausch + Lomb Announces Topline Results From The First Phase 3 Trial Of NOV03 In Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-lomb-announces-topline-results-from-the-first-phase-3-trial-of-nov03-in-dry-eye-disease-associated-with-mgd/2479072/Bausch + Lomb and Novaliq announced statistically significant topline data from the first phase 3 trial (GOBI trial) evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (D
- Santen Announces Global Research Initiative to Study and Develop New Treatments for Glaucomahttps://modernod.com/news/santen-announces-global-research-initiative-to-study-and-develop-new-treatments-for-glaucoma/2479067/Santen announced a research initiative with scientists from Massachusetts Eye and Ear, and Ulster University, UK, to research and develop novel treatments for glaucoma. The aim
- LumiThera Announces Topline Data in the European Multicenter LIGHTSITE II Study to Treat Dry AMDhttps://modernod.com/news/lumithera-announces-topline-data-in-the-european-multicenter-lightsite-ii-study-to-treat-dry-amd/2479059/LumiThera announced positive findings in its LIGHTSITE II multicenter clinical trial in dry age-related macular degeneration (AMD) patients. The prospective, double-masked, randomized, multicenter, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight re
- J&J Vision Announces Collaboration with Menicon to Bring Forward Contact Lenses for Childrenhttps://modernod.com/news/jj-vision-announces-collaboration-with-menicon-to-bring-forward-contact-lenses-for-children/2479057/Johnson & Johnson Vision announced a global strategic collaboration with Menicon, a manufacturer of contact lenses. As part of the collaboration, Menicon will develop and manufacture the contact lenses to help manage the progression of myopia in children. Johnson & Johnson Vision will foc
- Neurophth Announces IND Approval in China for Leber Hereditary Optic Neuropathy Gene Therapyhttps://modernod.com/news/neurophth-announces-ind-approval-in-china-for-leber-hereditary-optic-neuropathy-gene-therapy/2479055/Neurophth Biotechnology announced the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved the company’s investigational new drug (IND) application of NR082 (recombinant adeno-associated virus serotype 2 carrying ND4 gene; rAAV2-ND
- Eyenovia Announces Appointment of Julia Haller, MD, to its Board of Directorshttps://modernod.com/news/eyenovia-announces-appointment-of-julia-haller-md-to-its-board-of-directors/2479041/Eyenovia announced the appointment of Julia Haller, MD, to its Board of Directors. “We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” Sean Ianchulev, MD, PhD, Chief Executive Officer and Chief Medical
- AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Markethttps://modernod.com/news/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market/2479036/AffaMed Therapeutics and SIFI S.p.A. announced they have entered into an agreement to establish a joint venture to develop, manufacture and commercialize premium IOLs in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong. AffaMed will provide funding for growth
- Surface Ophthalmics Announces Preeya K. Gupta, MD, as Chief Medical Advisorhttps://modernod.com/news/surface-ophthalmics-announces-preeya-k-gupta-md-as-chief-medical-advisor/2479032/Surface Ophthalmics announced the appointment of Preeya K. Gupta, MD, as Chief Medical Advisor (CMA). Dr. Gupta will consult with Surface Ophthalmics leaders and lend her expertise, particularly in dry eye disease, to help guide Surface’s three clinical progra
- Aerie Pharmaceuticals Announces Publication of Peer-Reviewed Paper Evaluating the Treatment Effect of Netarsudil on Outflow Function in Steroid-Induced Glaucomahttps://modernod.com/news/aerie-pharmaceuticals-announces-publication-of-peer-reviewed-paper-evaluating-the-treatment-effect-of-netarsudil-on-outflow-function-in-steroid-induced-glaucoma/2479030/Aerie Pharmaceuticals announced the publication of a peer-reviewed paper in eLife entitled, “Antifibrotic activity of a rho-kinase inhibitor restores outflow function and intraocular pressure homeostasis.” This paper evaluates the treatment effect of netarsudil, marketed as Rhopressa (ne
- Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 Drug Candidate in Greater Chinahttps://modernod.com/news/tarsus-pharmaceuticals-and-lianbio-announce-strategic-partnership-to-develop-and-commercialize-tp-03-drug-candidate-in-greater-china/2479026/Tarsus Pharmaceuticals and LianBio announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and M